Gynecologic Oncology

In this fifth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss PD-1 blockade, potential biomarkers of response to treatment with immunotherapy, and the potential for these agents in the neoadjuvant setting.

Ritu Salani, MD, MBA, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.

The European Commission has approved cemiplimab-rwlc monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy.

The panel shares how they determine a treatment regimen for patients with advanced endometrial cancer taking into consideration fertility and family planning, hereditary conditions, and comorbidities.

Kathleen Lutz, RN, NP-BC WH, presents a 76-year-old woman with advanced endometrial cancer, and the panel assesses the chosen treatment regimens.

Dr Crane discusses why Atrium Health decided to launch a gyn onc fellowship, how she helps fellows navigate the current political landscape while maintaining high-level care, and how she tries to model a good work-life balance for her trainees.

Onatasertib plus toripalimab elicited an objective response rate of 52.4% in patients with relapsed or metastatic cervical cancer, irrespective of PD-L1 expression.

In this fourth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight long-term survival data reported with immunotherapy approaches in patients with gynecologic cancers.

Pratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.

Ritu Salani, MD, MBA, discusses updates in treating endometrial cancer.

Ursula A. Matulonis, MD, discusses the significance of the FDA approval of mirvetuximab soravtansine-gynx in patients with folate receptor α–positive, platinum-resistant ovarian cancer.

The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of select patients with folate receptor α–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Cheryl Saenz, MD, discusses the need for ongoing research efforts in cervical cancer.

At the request of the FDA, GlaxoSmithKline plc will restrict the second-line maintenance indication for niraparib to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA mutations.

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

In this third episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, review the 5 C's to consider when conducting research in gynecologic cancers and beyond.

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

Pratibha Binder, MD, discusses key trials improving the array of treatment options for patients with endometrial cancer.

In this second episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss the safety and efficacy of immunotherapy vs standard chemotherapy in patients with gynecologic cancers.

Before closing out their conversation on endometrial cancer, Kathleen Moore and David O’Malley summarize unmet needs in the field and share a few clinical pearls on managing patients with the disease.

Ritu Salani, MD, MBA, discusses the importance of histological subtyping and molecular profiling in developing treatment strategies and improving outcomes for patients with endometrial cancer.

In this first episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, explain how immunotherapy has changed practice for the treatment of patients with gynecologic cancers.

Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.

Shared insight into novel biomarkers and potential drug targets being explored for treatment of metastatic endometrial cancer.

Experts discuss ongoing clinical trials focused on moving second-line and higher targeted therapies, including immunotherapy, into the frontline setting for mEC, and then comment on how these advances might impact treatment paradigms and patient outcomes.